Hostname: page-component-7b7567c8c-wxvwp Total loading time: 0 Render date: 2026-11-16T15:52:20.364Z Has data issue: false hasContentIssue false

Severity of depression and response to antidepressants: GENPOD randomised controlled trial

Published online by Cambridge University Press:  02 January 2018

Nicola J. Wiles*
Affiliation:
School of Social and Community Medicine, University of Bristol, Bristol
Jean Mulligan
Affiliation:
School of Social and Community Medicine, University of Bristol, Bristol
Tim J. Peters
Affiliation:
School of Social and Community Medicine and School of Clinical Sciences, University of Bristol, Bristol
Philip J. Cowen
Affiliation:
Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford
Victoria Mason
Affiliation:
Psychological Sciences, University of Worcester, Worcester
David Nutt
Affiliation:
Department of Neuropsychopharmacology, Imperial College, London
Deborah Sharp
Affiliation:
School of Social and Community Medicine, University of Bristol, Bristol
Debbie Tallon
Affiliation:
School of Social and Community Medicine, University of Bristol, Bristol
Laura Thomas
Affiliation:
School of Social and Community Medicine, University of Bristol, Bristol
Michael C. O'Donovan
Affiliation:
MRC Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, Cardiff
Glyn Lewis
Affiliation:
School of Social and Community Medicine, University of Bristol, Bristol, UK
*
Nicola J. Wiles, Academic Unit of Psychiatry, School of Social and Community Medicine, University of Bristol, Oakfield House, Oakfield Grove, Clifton, Bristol BS8 2BN, UK. Email: nicola.wiles@bristol.ac.uk
Rights & Permissions [Opens in a new window]

Abstract

Background

Antidepressant prescribing is widespread. Nonetheless, response to antidepressants is variable. If it was possible to predict response to medication and thus tailor treatment accordingly, this would not only improve patient outcomes but may also have economic benefits.

Aims

To test the hypothesis that individuals with more severe depression would benefit more from noradrenaline reuptake inhibitors (NARIs) than selective serotonin reuptake inhibitors (SSRIs) compared with individuals with less severe depression.

Method

Individuals recruited from UK primary care who met ICD-10 criteria for a depressive episode and scored 15 or more on the Beck Depression Inventory (BDI) were randomised to either an SSRI (citalopram 20mg daily) or a NARI (reboxetine 4mg twice daily). Randomisation was by means of a remote automated telephone system. The main outcome was depressive symptoms measured by the BDI total score 6 weeks after randomisation. (Trial registration: ISRCTN31345163.)

Results

In total, 601 participants were randomised (citalopram: n = 298, reboxetine: n = 303). Ninety-one per cent were followed up at 6 weeks (citalopram: n = 274, reboxetine: n = 272). There was little evidence to support an interaction between treatment and severity of depression (interaction term: 0.02, 95% CI −0.59 to 0.62, P = 0.96). Adjustment for potential confounders (age, gender, employment status, history of depression, number of life events and social support) did not affect the findings (interaction term: 0.06, 95% CI −0.54 to 0.66, P = 0.85).

Conclusions

Treatment with NARIs does not confer any advantage over SSRI treatment for outcome in those with more severe depressive illness presenting in primary care.

Information

Type
Papers
Copyright
Copyright © 2012 The Royal College of Psychiatrists 
Figure 0

TABLE 1Characteristics of participants at baseline according to depression severity

Figure 1

TABLE 2Means and adjusted differences in Beck Depression Inventory scores at 6 weeks, in the citalopram and reboxetine groups, by depression severity (split into two groups at the median)

Figure 2

TABLE 4Proportion of participants with a Beck Depression Inventory (BDI) score of less than 10 (‘remission’) at 6 weeks

Figure 3

TABLE 3Additional analyses to test for differential effects on Beck Depression Inventory scores at 6 weeks in patients with most severe depression (CIS-R depression score ⩾19)

Supplementary material: PDF

Wiles et al. supplementary material

Supplementary Table S1-S4

Download Wiles et al. supplementary material(PDF)
PDF 48.5 KB

This journal is not currently accepting new eletters.

eLetters

No eLetters have been published for this article.